Table 5

Secondary outcomes in COPD patients 3 and 6 months after an inhaled corticosteroid or placebo

Outcome measureBaseline5-150 (after prednisone)At 3 months change from baseline5-151Treatment difference5-151At 6 months change from baseline5-151Treatment difference5-151
Budesonide (n=39)Placebo (n=40)Budesonide (n=38)Placebo
(n=34)
Budesonide (n=36)Placebo
(n=30)
Exercise capacity:
6-min walking test5-152 (m)311 (61)272 (59)−22
(−35 to −8)
−6
(−21 to 8)
−16
(−35 to 4)
−15
(−26 to −3)
13
(−1.0 to 27)
−28
(−45 to −10)
 Dyspnoea with exertion5-153 (m)5.1 (1.7)5.6 (1.9)0.8
(0 to 1.6)
1.0
(0.3 to 1.8)
−0.2
(−1.3 to 0.8)
0.7
(−0.1 to 1.5)
0.6
(−0.1 to 1.4)
0.1
(−1.0 to 1.1)
Quality of life5-155:
 Dyspnoea19.9 (6.2)19.5 (5.8)−1.7
(−3.0 to 0.5)
−0.8
(−3.7 to 2.2)
−0.9
(−4.4 to 2.5)
−1.8
(−3.9 to 0.2)
−0.5
(−2.3 to −1.3)
−1.3
(−4.1 to 1.5)
 Emotion37.9 (6.9)36.2 (9.6)1.1
(−1.2 to 3.5)
−1.3
(−4.3 to 1.8)
2.4
(−1.3 to 6.0)
−1.9
(−5.3 to 1.4)
−0.6
(−3.4 to 2.2)
−1.3
(−5.7 to 3.1)
 Fatigue20.7 (3.6)19.3 (5.6)−1.6
(−3.2 to 0)
−1.8
(−3.7 to 0.2)
0.2
(−2.2 to 2.6)
−3.0
(−4.9 to −1.2)
−1.4
(−3.1 to 0.3)
−1.6
(−4.1 to 0.9)
 Mastery21.4 (4.2)21.7 (5.8)0.5
(−1.1 to 2.1)
−1.4
(−3.2 to 0.3)
1.9
(−0.4 to 4.2)
−0.5
(−2.4 to 1.4)
−1.3
(−3.0 to 0.5)
0.8
(−1.8 to 3.4)
  • 5-150 Values presented are the mean and SD in parentheses.

  • 5-151 Values presented are the mean and the 95% CI in parentheses.

  • 5-152 Values presented are the maximum distance that the patient can walk in 6 min.

  • 5-153 Dyspnoea was assessed immediately after the 6-min walking test using a 10-cm VAS anchored by the terms “extremely short of breath” (a score of 0) and “no shortness of breath” (a score of 10).

  • 5-155 Scores for quality of life are from worst to best: dyspnoea, 5 to 35; fatigue, 4 to 28; emotion, 7 to 49; mastery, 4 to 28.